Literature DB >> 17933521

Intracrinology of estrogens and androgens in breast carcinoma.

Hironobu Sasano1, Takashi Suzuki, Yasuhiro Miki, Takuya Moriya.   

Abstract

Intratumoral metabolism and synthesis of biologically active steroids such as estradiol and 5alpha-dihydrotestosterone as a result of interactions of various enzymes are considered to play very important roles in the pathogenesis and development of hormone-dependent breast carcinoma. Among these enzymes involved in estrogen metabolism, intratumoral aromatase play an important role in converting androgens to estrogens in situ from serum and serving as the source of estrogens, especially in postmenopausal patients with breast carcinoma. However, other enzymes such as 17beta-hydroxysteroid dehydrogenase (17beta-HSD) isozymes, estrogen sulfatase (STS), and estrogen sulfotransferase, which contribute to in situ availability of biologically active estrogens, also play pivotal roles in this intratumoral estrogen production above. Androgen action on human breast carcinoma has not been well-studied but are considered important not only in hormonal regulation but also other biological features of carcinoma cells. Intracrine mechanisms also play important roles in androgen actions on human breast carcinoma cells. Among the enzymes involved in biologically active androgen metabolism and/or synthesis, both 17beta-hydroxysteroid dehydrogenase type 5 (17betaHSD5; conversion from circulating androstenedione to testosterone) and 5alpha-reductase (5alphaRed; reduction of testosterone to DHT (5alpha-dihydrotestosterone) were expressed in breast carcinoma tissues, and in situ production of DHT has been proposed in human breast cancer tissues. However, intracrine mechanisms of androgens as well as their biological or clinical significance in the patients with breast cancer have not been fully elucidated in contrast to those in estrogens.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17933521     DOI: 10.1016/j.jsbmb.2007.09.012

Source DB:  PubMed          Journal:  J Steroid Biochem Mol Biol        ISSN: 0960-0760            Impact factor:   4.292


  28 in total

1.  Adult body size and physical activity in relation to risk of breast cancer according to tumor androgen receptor status.

Authors:  Xuehong Zhang; A Heather Eliassen; Rulla M Tamimi; Aditi Hazra; Andrew H Beck; Myles Brown; Laura C Collins; Bernard Rosner; Susan E Hankinson
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2015-04-08       Impact factor: 4.254

2.  Increased 5α-reductase type 2 expression in human breast carcinoma following aromatase inhibitor therapy: the correlation with decreased tumor cell proliferation.

Authors:  Niramol Chanplakorn; Pongsthorn Chanplakorn; Takashi Suzuki; Katsuhiko Ono; Lin Wang; Monica S M Chan; Loo Wing; Christopher C P Yiu; Louis Wing-Cheong Chow; Hironobu Sasano
Journal:  Horm Cancer       Date:  2011-02       Impact factor: 3.869

3.  Expression of 11β-hydroxysteroid dehydrogenase type 1 in breast cancer and adjacent non-malignant tissue. An immunocytochemical study.

Authors:  Lu Lu; Gang Zhao; Van Luu-The; Johanne Ouellet; Zhinmin Fan; Fernand Labrie; Georges Pelletier
Journal:  Pathol Oncol Res       Date:  2011-01-26       Impact factor: 3.201

4.  Stability of 15 estrogens and estrogen metabolites in urine samples under processing and storage conditions typically used in epidemiologic studies.

Authors:  Barbara J Fuhrman; Xia Xu; Roni T Falk; Susan E Hankinson; Timothy D Veenstra; Larry K Keefer; Regina G Ziegler
Journal:  Int J Biol Markers       Date:  2010 Oct-Dec       Impact factor: 2.659

5.  The CCAAT box binding transcription factor, nuclear factor-Y (NF-Y) regulates transcription of human aldo-keto reductase 1C1 (AKR1C1) gene.

Authors:  Rajash Pallai; Henry Simpkins; Jianli Chen; Hemant K Parekh
Journal:  Gene       Date:  2010-03-23       Impact factor: 3.688

Review 6.  Aromatase, estrone sulfatase, and 17β-hydroxysteroid dehydrogenase: structure-function studies and inhibitor development.

Authors:  Yanyan Hong; Shiuan Chen
Journal:  Mol Cell Endocrinol       Date:  2010-10-01       Impact factor: 4.102

Review 7.  Interindividual differences in response to plant-based diets: implications for cancer risk.

Authors:  Johanna W Lampe
Journal:  Am J Clin Nutr       Date:  2009-03-18       Impact factor: 7.045

8.  Inhibition of cyclin D1 expression by androgen receptor in breast cancer cells--identification of a novel androgen response element.

Authors:  Marilena Lanzino; Diego Sisci; Catia Morelli; Cecilia Garofalo; Stefania Catalano; Ivan Casaburi; Claudia Capparelli; Cinzia Giordano; Francesca Giordano; Marcello Maggiolini; Sebastiano Andò
Journal:  Nucleic Acids Res       Date:  2010-04-26       Impact factor: 16.971

9.  Ferroptosis: a new unexpected chance to treat metastatic melanoma?

Authors:  Mara Gagliardi; Valentina Saverio; Romina Monzani; Eleonora Ferrari; Mauro Piacentini; Marco Corazzari
Journal:  Cell Cycle       Date:  2020-08-20       Impact factor: 4.534

10.  In situ aromatase expression in primary tumor is associated with estrogen receptor expression but is not predictive of response to endocrine therapy in advanced breast cancer.

Authors:  Anne E Lykkesfeldt; Katrine L Henriksen; Birgitte B Rasmussen; Hironobu Sasano; Dean B Evans; Susanne Møller; Bent Ejlertsen; Henning T Mouridsen
Journal:  BMC Cancer       Date:  2009-06-16       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.